Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: Scenesse · Melanotan I (historical naming)
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Melanocortin analogue peptide
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Stimulates eumelanin production.
Evidence and critical reading
Reported scientific and empirical uses
Skin, hair and cosmetics
The authorized context reviewed is erythropoietic-protoporphyria phototoxicity. Cosmetic tanning in handbooks is a different claim and does not inherit that authorization.
Human evidence
Clinical evidence concerns phototoxicity in erythropoietic protoporphyria, not cosmetic tanning.
Preclinical evidence
Pigment effects do not make UV exposure harmless.
Critical reading and limitations
The same nominal mass does not make an implant, injectable solution and spray equivalent. Release, exposure and population differ. Dosage form must stay beside each quantity so implant dosing cannot be mistaken for a commercial-vial regimen.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Scenesse current US label
16 mg · Amount per defined-product implant
- Frequency
- One implant every two months.
- Duration
- Not stated on selected page.
- Route
- Subcutaneous implant
- Context
- Adults with EPP and phototoxicity history per US label.
- Presentation
- Sustained-release implant, not a powder vial.
- Interpretation
- Not equivalent to a “Melanotan I” vial regimen.
REG-SCE · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Human-study exposure
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Empirical handbook
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Regulation and safety
Jurisdiction-specific regulatory context
US/EU: authorized Scenesse implant for EPP under label conditions; internet Melanotan I products do not inherit authorization.
Adverse effects and unknowns
Nausea, headache and implant-site effects; restrictions and surveillance are product-specific.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
afamelanotide · 23 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT06388642 · Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria PatientsRegistry status: CompletedLast update posted: July 27, 2026Query verification: October 16, 2026
NCT06109649 · A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With VitiligoRegistry status: Active, not recruitingLast update posted: July 8, 2025Query verification: October 16, 2026
NCT05854784 · Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP)Registry status: CompletedLast update posted: April 27, 2025Query verification: October 16, 2026
Source issues and references
EPP implant authorization is not approval for cosmetic tanning or a Melanotan I vial. · manual02 · Page 163
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- EMA-SCE
October 16, 2026
- R32
- REG-SCE
October 16, 2026
- manual02
peptide-protocols-volume-one.pdf
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026